Diffuse Large B Cell Lymphoma ICD-10-CM Codes | 2025

What are Diffuse Large B Cell Lymphoma ICD-10-CM Codes?

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, defined by the aggressive and rapid proliferation of large B cells. It typically involves lymph nodes, but can also affect extranodal and solid organ sites, including the gastrointestinal tract, bone marrow, and central nervous system.

Accurate documentation using the correct ICD-10 codes for diffuse large B-cell lymphoma is crucial for treatment planning, research, and reimbursement. The updated 2025 ICD-10-CM system includes detailed codes for specific anatomic sites, remission status, and related cell lymphoma conditions.

• C83.30 – Diffuse large B-cell lymphoma, unspecified site
• C83.31 – Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
• C83.32 – Diffuse large B-cell lymphoma, intrathoracic lymph nodes
• C83.390 – Primary central nervous system lymphoma
• C83.3A – Diffuse large B-cell lymphoma, in remission
• C83.80 – Other non-follicular lymphoma, unspecified site
• C83.82 –Other non-follicular lymphoma, intrathoracic lymph nodes
• C83.83 – Other non-follicular lymphoma, intra-abdominal lymph nodes
• C83.89 – Other non-follicular lymphoma, extranodal and solid organ sites
• C85.10 – Unspecified B-cell lymphoma, unspecified site

Which Diffuse Large B Cell Lymphoma ICD-10-CM Codes are billable?

All the following codes are valid and billable in 2025.

Clinical information

Diffuse large B-cell lymphoma (DLBCL) is classified as a mature B-cell neoplasm and falls under the broader category of malignant lymphomas. It shares characteristics with other high-grade lymphomas, such as anaplastic large cell lymphoma and follicular lymphoma that have undergone transformation.

Common sites of involvement include lymph nodes in the head, face, and neck; axillary and upper limb nodes; and multiple nodal regions, including the inguinal area and skin-associated lymphoid tissue. In rarer cases, bronchial-associated lymphoid tissue may also be affected.

Clinically, DLBCL often presents with enlarged lymph nodes and systemic "B symptoms" such as fever, night sweats, and unintentional weight loss. Extranodal involvement is also observed in some cases, with the gastrointestinal tract, central nervous system (CNS), and skin being common sites. Diagnosis is confirmed through a biopsy of the affected lymph node or organ, followed by immunohistochemical staining and molecular testing for markers such as MYC and BCL2. The Ann Arbor staging system is typically used for disease classification.

First-line treatment for DLBCL usually involves the R-CHOP chemotherapy regimen, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. In patients with refractory or relapsed disease, management options may include stem cell transplantation, CAR T-cell therapy, or enrollment in clinical trials exploring monoclonal antibody therapies.

Prognosis depends on several factors, including the disease stage at diagnosis, patient age, overall health, and underlying genetic markers. With prompt and appropriate treatment, early-stage DLBCL has a high likelihood of cure.

Synonyms include

• Diffuse Large B-Cell Non-Hodgkin Lymphoma
• DLBCL
• Large Cell Lymphoma
• High-Grade B-Cell Lymphoma
• Aggressive B-Cell Lymphoma